LH Laboratory Corp. Of America Dashboard

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through its unparalleled diagnostics and drug development capabilities, company provides insights and accelerates innovations to improve health and improve lives. With more than 70,000 employees, Labcorp serves clients in more than 100 countries. Labcorp reported revenue of $14 billion in FY2020.

Company profile

Ticker

Exchange

NYSE

Website

www.labcorp.com

CEO

David King

Incorporated

Delaware

Location

North Carolina

Fiscal year end

Dec 31

Sector

Manufacturing > Dental Laboratories

Industry (SIC)

Services - Medical Laboratories

Quest Diagnostics • Radnet • Burning Rock Biotech • Guardant Health • Genomic Health • Invitae • Natera • Progenity • Enzo Biochem • Centogene ...

Former names

NATIONAL HEALTH LABORATORIES HOLDINGS INC

SEC CIK

0000920148

Corporate docs

Articles of Incorporation & Bylaws

IRS number

133757370

LH stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Deutsche Bank Maintains Buy on Laboratory Corp, Raises Price Target to $330

30 Jul 21

Deutsche Bank analyst Pito Chickering maintains Laboratory Corp (NYSE:LH) with a Buy and raises the price target from $297 to $330.

Stocks That Hit 52-Week Highs On Friday

30 Jul 21

On Friday morning, 154 companies achieved new highs for the year.

Mizuho Maintains Buy on Laboratory Corp, Raises Price Target to $318

30 Jul 21

Mizuho analyst Ann Hynes maintains Laboratory Corp (NYSE:LH) with a Buy and raises the price target from $310 to $318.

Stocks That Hit 52-Week Highs On Thursday

29 Jul 21

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs

29 Jul 21

Press releases

Pro users get this 30m faster

Labcorp Announces 2021 Second Quarter Results

29 Jul 21

Company Raises Full Year Guidance Revenue: Q2 of $3.8 billion, versus $2.8 billion last year Diluted EPS: Q2 of $4.76, versus $2.37 last year Adjusted EPS: Q2 of $6.13, versus $2.57 last year Free Cash Flow: Q2

Labcorp to Announce Second Quarter Financial Results on July 29, 2021

2 Jul 21

Labcorp (NYSE:LH), a leading global life sciences company, will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 29, 2021. The company will host a conference call

Labcorp Launches Companion Diagnostic for Amgen's Newly-approved Lung Cancer Therapy

1 Jul 21

Test Expands Labcorp's Leadership In Bringing Testing Solutions for New Precision Medicines Used to Treat Patients With Lung Cancer Labcorp® (NYSE:LH), a leading global life sciences company, today announced the

Cybin Inc. Releases Annual Financials and Provides Business Highlights

28 Jun 21

Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance

22 Jun 21

Calendar

4 May 21

2 Aug 21

31 Dec 21

Financial summary

Financial statements Chart LH financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

LH insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
7 Jun 21	van der Vaart Sandra D	Common Stock	Sell	Dispose S	No	Yes	266.56	4,500	1.2M	5,237.042
7 Jun 21	van der Vaart Sandra D	Common Stock	Option exercise	Aquire M	No	Yes	84.86	4,500	381.87K	9,737.042
7 Jun 21	van der Vaart Sandra D	NQSO Common Stock	Option exercise	Dispose M	No	No	84.86	4,500	381.87K	4,500
6 May 21	Kirchgraber Paul R	Common Stock	Sell	Dispose S	No	No	276.55	2,500	691.38K	7,844
3 May 21	Jean-luc Belingard	Common Stock	Sell	Dispose S	No	No	269.1551	2,600	699.8K	15,569
3 May 21	Jean-luc Belingard	Common Stock	Option exercise	Aquire M	No	No	98.49	2,600	256.07K	18,169
3 May 21	Jean-luc Belingard	NQSO Common Stock	Option exercise	Dispose M	No	No	98.49	2,600	256.07K	0
3 Apr 21	Kirchgraber Paul R	Common Stock	Payment of exercise	Dispose F	No	No	252.67	452	114.21K	10,344
3 Apr 21	Kirchgraber Paul R	Common Stock	Option exercise	Aquire M	No	No	0	1,010	0	10,796
3 Apr 21	Kirchgraber Paul R	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,010	0	6,781

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

LH institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

88.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	875	871	+0.5%
Opened positions	104	144	-27.8%
Closed positions	100	52	+92.3%
Increased positions	285	302	-5.6%
Reduced positions	319	286	+11.5%

13F shares	Current	Prev Q	Change
Total value	21.99B	17.61B	+24.9%
Total shares	86.23M	86.63M	-0.5%
Total puts	279.1K	396.1K	-29.5%
Total calls	573.7K	486.7K	+17.9%
Total put/call ratio	0.5	0.8	-40.2%

Largest owners	Shares	Value	Change
Vanguard	10.63M	$2.71B	+2.2%
BLK Blackrock	8.08M	$2.06B	+3.2%
STT State Street	4.03M	$1.03B	-0.8%
Wellington Management	3.33M	$848.03M	+21.4%
FMR	2.15M	$547.44M	+26.1%
BEN Franklin Resources	1.76M	$449.78M	-4.2%
Geode Capital Management	1.71M	$434.97M	+5.0%
BAC Bank Of America	1.59M	$404.7M	+10.2%
Melvin Capital Management	1.5M	$382.55M	+73.4%
Dimensional Fund Advisors	1.4M	$357.16M	-0.4%

Largest transactions	Shares	Bought/sold	Change
Viking Global Investors	1.08M	+986.72K	+1044.1%
Norges Bank	0	-909.99K	EXIT
Nordea Investment Management Ab	1.23M	-671.55K	-35.3%
Melvin Capital Management	1.5M	+635K	+73.4%
Wellington Management	3.33M	+587.09K	+21.4%
Suvretta Capital Management	0	-569.61K	EXIT
Citadel Advisors	662.32K	+444.5K	+204.1%
FMR	2.15M	+444.19K	+26.1%
Alliancebernstein	1.27M	+393.57K	+44.7%
Assenagon Asset Management	155.76K	-344.68K	-68.9%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Risks

There can be no assurance that the Company’s review of its structure and capital allocation strategy will enhance shareholder value or result in any changes to its structure or capital allocation strategy, and speculation and uncertainty regarding the outcome of this review may adversely impact the business, financial condition, and results of operations.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: accelerated, advisor, assay, assistance, autoimmune, BBB, clear, commenced, conclusion, confident, consecutive, copy, DD, diligence, distraction, double, Dx, Exhibit, factor, Foy, Goldman, lesser, letter, LLC, modification, momentum, motivating, Myriad, narrowing, Petition, prospective, pursue, Qualitative, RA, rebranding, refinance, reflect, reflected, reiterating, repaid, retrospective, rheumatoid, skilled, speculation, swingline, talented, therapeutic, unlock, Vectra, vital

Removed: acceptable, accessibility, accrual, accurately, activity, acutely, Additionally, Aid, Alma, alternative, application, arrangement, assert, attack, breadth, bringing, broad, broader, cancellation, capacity, capitalizing, car, carry, cascading, CDC, CDD, certify, challenged, characterization, Chiltern, cleaning, closed, closely, collaborate, combination, comfort, compliant, concurrent, conditionally, consisting, constitute, consulting, context, continue, continued, continuity, continuously, covenant, create, created, credited, criteria, critical, CRO, CRP, curtailment, daily, declared, decline, deep, deeply, default, delayed, delaying, delivering, demanded, dependent, detect, determine, developing, differentiation, difficult, discretionary, disinfection, disposition, distancing, distributed, divert, diverted, divested, downturn, driven, earn, Eastern, EBITDA, eligible, emergency, ending, engineering, enhanced, enhancing, Envigo, equipment, evaluated, exceeded, exempt, expanded, expanding, experience, exploit, extend, extended, faster, FDA, fine, flexibility, flexible, focused, forced, forma, frequency, fund, funded, generate, geographic, German, guidance, guiding, half, hand, Haro, headroom, HHS, hinder, hosting, hour, hygiene, IA, Ignacio, implicit, important, impossible, inadequate, inclusive, infection, inform, innovative, insufficient, integrated, intended, Jan, kit, launched, LCD, legacy, longer, macroeconomic, magnitude, match, merit, methodology, misclassified, mission, Mitchell, mitigation, modified, monitor, month, nearby, NEC, nonclinical, nonqualified, nonrenewal, nurse, opening, outbreak, partial, participating, Pennsylvania, PEP, periodic, phase, phishing, physical, policy, positive, preclude, predict, predicted, predominantly, presence, prioritization, prioritize, pro, prohibited, projected, protective, prove, publicity, rapidly, reach, receive, recommended, registry, remote, remotely, renewable, repay, require, restrictive, routine, Sacramento, salary, sale, sanitation, scientific, secure, selected, significance, site, small, solid, specifically, speed, spread, stability, strained, subsequently, suffer, supplemental, supportable, susceptible, suspended, suspending, sweeping, targeting, TCJA, technological, temporarily, terminal, tested, threat, training, trial, turmoil, unavailable, unfavorably, unforeseen, unfunded, voluntary, vulnerable, waiting, waiver, worldwide, worsen

From filing 10-Q 2021 Q1